Hematoma Characteristics and Functional Outcome Do Not Differ in NOAC Versus VKA Associated Intracerebral Hemorrhage (P6.060)
Objective: To compare patients with VKA ICH versus NOAC ICH regarding baseline characteristics, clinical and radiological findings on admission, mortality and functional outcome. Background: There are only few studies with very low patient numbers comparing the clinical characteristics, radiological findings and functional outcome of patients with non vitamin K antagonist oral anticoagulants (NOACs) compared to vitamin K(VKA) associated ICH. Methods: In this monocenter observational study we screened our prospective ICH database for patients with NOAC and VKA related ICH between 2008 2015. We compared baseline clinical and radiological parameters between individuals with NOAC versus VKA related ICH. Further we assessed functional outcome at 3 months using the modified Rankin scale (mRS) To minimize potential bias by indication we performed a propensity score matching. Results: We identified 17 patients with NOAC (13/2/2 Rivaroxaban/Apixaban/Dabigatran) and 95 with VKA associated ICH. Patients with NOAC ICH had poorer pre admission functional status and more often history of ICH compared to VKA ICH patients. Baseline clinical status (GCS, NIHSS) as well as radiological findings (ICH volume and location, intraventricular involvement, frequency of hematoma expansion) showed no significant differences among both groups. There were no differences in mortality and functional outcome (mRS=0 3/4 6: DOAK 3/14 vs. VKA 27/68; p=0.398) After propensity score matching adjusting for different baseline characteristics there were still no differences regarding outcome (mRS=0 3/4 6: DOAK 4/12 vs. VKA 11/27; p=0.515) Conclusions: This analysis provided no evidence of differences in radiological findings or clinical outcome between patients with VKA vs. NOAC associated ICH. Larger datasets of population based cohorts or registries may provide further information about whether or not NOAC ICH differs from VKA ICH in baseline and outcome findings. Disclosure: Dr. Gerner has nothing to disclose. Dr. Luecking has nothing to disclose. Dr. Koehrmann has nothing to disclose. Dr. Huttner has nothing to disclose.